GANX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 11.00%

Insider Buying (Last 12 Months): $115,800.00

Insider Selling (Last 12 Months): $506.76

Gain Therapeutics Insider Trading History Chart

Gain Therapeutics Share Price & Price History

^$3.17

▼ -0.01 (-0.31%)

As of 04/22/2024 01:00 AM ET

Days: 30 | 90 | 365

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

Gain Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/28/2024	Jeffrey Scott Riley	Director	Buy	30,000	$3.86	$115,800.00	30,000
12/21/2023	Matthias Alder	CEO	Sell	206	$2.46	$506.76	5,286
5/25/2022	Eric I Richman	CEO	Buy	2,482	$2.58	$6,403.56	217,729
5/19/2022	Eric I Richman	CEO	Buy	4,000	$2.71	$10,840.00	205,991

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

SEC Filings (Institutional Ownership Changes) for Gain Therapeutics (NASDAQ:GANX)

11.97% of Gain Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Gain Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
1/16/2024	Raymond James & Associates	23,788	$78K	0.0%	-29.6%	0.184%
7/25/2023	Raymond James & Associates	33,400	$0.15M	0.0%	+67.0%	0.271%
5/8/2023	CM Management LLC	90,000	$0.43M	0.5%	-18.2%	0.740%
5/2/2023	Wealth Alliance Advisory Group LLC	12,502	$60K	0.0%	-33.3%	0.105%
4/14/2023	Raymond James & Associates	20,000	$96K	0.0%	-16.7%	0.168%
2/9/2023	CM Management LLC	110,000	$0.34M	0.4%	-12.0%	0.926%
1/17/2023	Wealth Alliance Advisory Group LLC	18,751	$59K	0.0%	-25.0%	0.158%
11/17/2022	Telemetry Investments L.L.C.	150,000	$0.49M	0.6%	-6.3%	1.263%
10/25/2022	Raymond James & Associates	24,000	$78K	0.0%	N/A	0.202%
10/12/2022	Wealth Alliance Advisory Group LLC	25,000	$82K	0.0%	N/A	0.210%
5/9/2022	CM Management LLC	125,000	$0.51M	0.4%	+38.9%	1.052%
2/3/2022	Advisor Group Holdings Inc.	10,050	$54K	0.0%	N/A	0.085%
2/2/2022	CM Management LLC	90,000	$0.49M	0.4%	+39.9%	0.758%
11/16/2021	Telemetry Investments L.L.C.	96,232	$0.72M	1.0%	+217.7%	0.810%
11/15/2021	Veritable L.P.	25,064	$0.19M	0.0%	N/A	0.211%
11/9/2021	Indie Asset Partners LLC	29,652	$0.22M	0.2%	N/A	0.250%
11/8/2021	CM Management LLC	64,327	$0.48M	0.4%	+543.3%	0.542%
8/17/2021	Bridgeway Capital Management LLC	50,000	$0.50M	0.0%	N/A	0.421%
8/16/2021	Telemetry Investments L.L.C.	30,293	$0.30M	0.4%	N/A	0.255%
8/11/2021	Banque Cantonale Vaudoise	3,000	$30K	0.0%	N/A	0.025%
8/10/2021	CM Management LLC	10,000	$100K	0.1%	N/A	0.084%
5/27/2021	Davidson Kempner Capital Management LP	15,000	$0.22M	0.0%	N/A	0.126%
5/19/2021	Worth Venture Partners LLC	15,532	$0.23M	0.1%	N/A	0.131%
5/18/2021	Millennium Management LLC	14,367	$0.21M	0.0%	N/A	0.121%
5/18/2021	Greenlight Capital Inc.	546,560	$8.16M	0.6%	N/A	4.602%
5/18/2021	Davidson Kempner Capital Management LP	15,000	$0.22M	0.0%	N/A	0.126%
5/18/2021	Jane Street Group LLC	22,754	$0.34M	0.0%	N/A	0.192%

Data available starting January 2016

Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Today's Range

Now: $3.17

$3.12

$3.43

50 Day Range

MA: $4.09

$3.09

$4.82

52 Week Range

Now: $3.17

$2.00

$5.65

Volume

53,675 shs

Average Volume

155,439 shs

Market Capitalization

$51.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Who are the company insiders with the largest holdings of Gain Therapeutics?: Gain Therapeutics' top insider investors include:
Eric I Richman (CEO)
Jeffrey Scott Riley (Director)
Matthias Alder (CEO)
Learn More about top insider investors at Gain Therapeutics.